Biegel et al. (1999) evaluated SMARCB1 as a candidate tumor suppressor in atypical teratoid/rhabdoid tumors (ATRT) across a cohort of 29 MRTs, which included 18 ATRTs [25]. Here, SMARCB1 is linked to atypical teratoid rhabdoid tumor.